Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $528000.0.

  • Precision Biosciences' Change in Accured Expenses fell 7415.57% to $528000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 110469.14%. This contributed to the annual value of -$2.1 million for FY2024, which is 19392.27% down from last year.
  • Latest data reveals that Precision Biosciences reported Change in Accured Expenses of $528000.0 as of Q3 2025, which was down 7415.57% from $677000.0 recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Change in Accured Expenses registered a high of $2.4 million during Q2 2022, and its lowest value of -$5.8 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is -$376736.8, with a median of $474000.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in Precision Biosciences' Change in Accured Expenses was 76760.56% (2022), while the steepest drop was 13998.14% (2022).
  • Quarter analysis of 5 years shows Precision Biosciences' Change in Accured Expenses stood at $2.4 million in 2021, then tumbled by 82.45% to $421000.0 in 2022, then soared by 464.61% to $2.4 million in 2023, then plummeted by 106.56% to -$156000.0 in 2024, then surged by 438.46% to $528000.0 in 2025.
  • Its Change in Accured Expenses stands at $528000.0 for Q3 2025, versus $677000.0 for Q2 2025 and -$5.1 million for Q1 2025.